Salermide

Discontinued Product

4127 has been discontinued.

View all Class III HDACs (Sirtuins) products.
说明: SIRT1 and SIRT2 inhibitor
化学名: N-[3-[[(2-Hydroxy-1-naphthalenyl)methylene]amino]phenyl]-α-methylbenzeneacetamide
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for Salermide

Salermide is a SIRT1 and SIRT2 inhibitor. Exhibits a stronger inhibitory effect on SIRT2 than on SIRT1 in vitro. Induces the reactivation of proapoptotic genes repressed by SIRT1 and causes massive apoptosis in cancer cells within 24 hours.

技术数据 for Salermide

分子量 394.47
公式 C26H22N2O2
储存 Store at +4°C
纯度 ≥98% (HPLC)
CAS Number 1105698-15-4
PubChem ID 53393948
InChI Key UADRPWLRVLBVBC-UHFFFAOYSA-N
Smiles O=C(C(C)C4=CC=CC=C4)NC1=CC=CC(/N=C/C3=C(O)C=CC2=CC=CC=C23)=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

按产品操作查看相关产品

查看全部 Class III HDAC (Sirtuin) Inhibitors

关键词: Salermide, Salermide supplier, sirt1, sirt2, sirtuin, sir2-like, inhibitors, inhibits, apoptosis, proapoptotic, antitumor, agents, Class, III, HDACs, (Sirtuins), 4127, Tocris Bioscience

篇 Salermide 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 Salermide 的引用文献。

Salermide 的评论

目前没有该产品的评论。 Be the first to review Salermide and earn rewards!

Have you used Salermide?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.